Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL
Kelly Dufraing, Francesca Fenizia, Emina Torlakovic, Nicola Wolstenholme, Zandra C. Deans, Étienne Rouleau, Mogens Vyberg, Suzanne Parry, Ed Schuuring, Elisabeth Dequeker, on behalf of IQNPath ABSL, Nicola Normanno, Melanie H. Cheetham, Simon Patton, Cleo Keppens, Kaat Van Casteren, J. Han van Krieken, Jenni Fairley, Maja Grassow-Narlik, Korinna Jöhrens, Julia Pagliuso
Abstract
In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA programs for different cancer types, test methods, and sample types. In 2013, a guideline was published on the requirements for organizing high-quality EQA programs in molecular pathology. Now, after six years, steps were taken to further harmonize these EQA programs as an initiative by IQNPath ABSL, an umbrella organization founded by various EQA providers. This revision is based on current knowledge, adds recommendations for programs developed for predictive biomarkers by in situ methodologies (immunohistochemistry and in situ hybridization), and emphasized transparency and an evidence-based approach. In addition, this updated version also has the aim to give an overview of current practices from various EQA providers.